Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 3/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295817 | 1.00 | LPL (0.39) | LPLLIPGALDH1A1TDP1CES2 | |
| Boric Acid SCHEMBL28902973 | 0.89 | CA4 (0.38) | LPLLIPGALDH1A1TDP1CES2 | |
| SCHEMBL14983378 | 0.83 | LPL (0.59) | LPLLIPGALDH1A1TDP1MAPK1 | |
| SCHEMBL9807128 | 0.81 | LPL (0.33) | LPLLIPG | |
| Phenylboronic Acid SCHEMBL7540976 | 0.81 | ENPP2 (0.61) | LPLLIPGTSHRCA1CA2 | |
| SCHEMBL14983387 | 0.77 | MAOA (0.43) | LPLLIPGALDH1A1MAPK1LMNA | |
| SCHEMBL19484959 | 0.75 | CYP2C19 (0.38) | LPLLIPGTSHRLMNA | |
| SCHEMBL7859911 | 0.75 | CYP2A6 (0.47) | ALDH1A1TDP1CES2CES1MAPK1 | |
| SCHEMBL1453305 | 0.73 | LPL (0.35) | LPLLIPGALDH1A1TDP1 | |
| SCHEMBL10361776 | 0.73 | LPL (0.35) | LPLLIPGALDH1A1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | INTREXON CORP (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | INTREXON CORP (US) | 2018-07-19 | — | — | US | disclosed |
| US-9944659-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944659-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160083403-A1 | Boron-Containing Diacylhydrazine Compounds | INTREXON CORPORATION | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083403-A1 | Boron-Containing Diacylhydrazine Compounds | BRDT, CD22, BCR | LPL 4096/4885LIPG 3424/4885ALDH1A1 3229/4885 |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | BRDT, CD22, BCR | LPL 4096/4885LIPG 3424/4885ALDH1A1 3229/4885 |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | BRDT, CD22, BCR | LPL 4096/4885LIPG 3424/4885ALDH1A1 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.